Corneal erosion is a common ocular condition that can cause significant pain and discomfort. It is characterized by a loss of the protective outer layer of the cornea, which can lead to sensitivity to light, blurred vision, and foreign body sensation. Recurrent corneal erosion (RCE) is a particularly problematic form of the condition in which the erosion occurs repeatedly. It is estimated that RCE affects between 0.2% and 4.3% of the population, and is more common in people with certain risk factors such as contact lens use, dry eye, and previous ocular surgery. The management of RCE is challenging due to its recurrent nature. Conventional treatments such as the use of topical antibiotics and topical steroids are often ineffective, and the condition can be difficult to control. In recent years, there have been a number of advances in the prevention and treatment of RCE, including the use of newer medications, surgical techniques, and lifestyle modifications. This article will discuss these new strategies for tackling recurrent corneal erosion.
Topical medications are commonly used to treat RCE, and there are a number of newer medications that have been developed in recent years. One of the most commonly used medications is the antibiotic moxifloxacin, which has been shown to reduce the frequency of recurrences. Other antibiotics such as ofloxacin, gatifloxacin, and levofloxacin have also been used with some success. In addition to antibiotics, other medications such as cyclosporine, tacrolimus, and corticosteroids have been used to reduce the inflammation associated with RCE. These medications can be used alone or in combination with antibiotics.
In some cases, surgical techniques may be used to treat RCE. These techniques include phototherapeutic keratectomy (PTK) and debridement. PTK is a procedure in which the affected corneal tissue is removed using a laser. This can reduce the frequency of recurrences and improve symptoms. Debridement is a procedure in which the affected corneal tissue is scraped away using a scalpel. This can help to remove any debris or bacteria that may be causing the erosion.
Lifestyle modifications can also be beneficial in the management of RCE. These include avoiding contact lenses, using artificial tears, and wearing protective eyewear. Contact lenses should be avoided in people with RCE, as they can increase the risk of recurrences. Artificial tears can help to reduce the symptoms associated with RCE, and protective eyewear can help to protect the eyes from further damage.
Recurrent corneal erosion is a challenging condition to manage due to its recurrent nature. There have been a number of advances in the prevention and treatment of RCE in recent years, including the use of newer medications, surgical techniques, and lifestyle modifications. These strategies can help to reduce the frequency of recurrences and improve symptoms. It is important to discuss any treatment options with an ophthalmologist to determine the best course of action.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation